News | Press Releases

August 4, 2023

Canon Medical announces release of Alphenix / Evolve Edition*¹, infusing real-time AI technology for Interventional Cardiology Suites

Otawara, Tochigi Prefecture, Japan, 4 August 2023 – Canon Medical announced that its new Angiography system, Alphenix / Evolve Edition is now available for commercial sale in Japan, Asian, African and European markets. Utilising deep learning technology in real-time, Alphenix / Evolve Edition is designed to enhance imaging while enabling reduced time and radiation dose during routine and complex percutaneous coronary intervention (PCI) and structural heart disease (SHD) procedures, improving safety for clinicians and patients.

Alphenix / Evolve Edition delivers a range of industry leading solutions for the Interventional Cardiology suite. Packaged under the αEvolve (alpha Evolve) technology umbrella of AI solutions, they provide real-time assistance that can instantaneously support key diagnostic and therapeutic decisions without interrupting procedural flow.

αEvolve Imaging utilises deep learning based noise reduction and multi-frequency processing to enable sharp and clear fluoroscopic imaging, which can deliver two times higher contrast-to-noise ratio compared to conventional image processing, reducing the reliance on digital acquisition

Dynamic Device Stabiliser (DDS) has been trained with deep learning to automatically detect balloon markers in real-time, magnifying and stabilising the image on a separate screen to assist stent visualisation and assessment during complex PCI procedures.

With the rise of SHD procedures such as left atrial appendage (LAA) closure, Echo Fusion*¹*² taps into deep learning intelligence to automatically identify the echocardiography probe and efficiently fuse the fluoroscopic and echo image without additional operator input.

In addition, Alphenix / Evolve Edition offers a new level of intelligence and efficiency for the modern Interventional angiography suite through existing technologies like 12x12 inch flat panel detector (FPD) technology that provide　complete procedural flexibility and Dose Tracking System (DTS) that provides real-time information on radiation dose.

“Interventional Cardiology departments are faced with increasing clinical demands, financial pressures, and the need for improved efficiency as the number and complexity of cases increase. To meet these challenges, we have introduced Alphenix / Evolve Edition” commented Kunitoshi Matsumoto, General Manager, Vascular Systems Division.

“We have rigorously tested these new AI technologies in both development and clinical phases, and are extremely confident they will have a big impact on clinical success in Interventional Cardiology. Clinical evaluation sites recently presented on their initial experiences at EuroPCR in Paris with very positive results” he continued.